---
figid: PMC10915323__ajcr0014-0407-f1
figtitle: Leveraging molecular targeted drugs and immune checkpoint inhibitors treat
  advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10915323
filename: ajcr0014-0407-f1.jpg
figlink: /pmc/articles/PMC10915323/figure/fig01/
number: F1
caption: The major signaling pathways of molecular targeted drugs. FL, FLT-3 ligand;
  FLT-3, FMS-like tyrosine kinase-3; GDNF, glial cell-derived neurotrophic factor;
  GFRα, GDNF family receptor α; RET, rearranged during transfection; HGF, hepatocyte
  growth factor; MET, mesenchymal-epithelial transition factor; SCF, stem cell factor;
  c-KIT, proto-oncogene proteins c-kit; EGF, epidermal growth factor; EGFR, epidermal
  growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular
  endothelial growth factor receptor; PDGF, platelet-derived growth factor; PDGFR,
  platelet-derived growth factor receptor; FGF, fibroblast growth factor; FGFR, fibroblast
  growth factor receptor; PI3K (phosphatidylinositol-3 kinase)/AKT/mammalian target
  of rapamycin (mTOR) signaling pathway; RAS/RAF/MEK/ERK signaling pathway.
papertitle: Leveraging molecular targeted drugs and immune checkpoint inhibitors treat
  advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
reftext: Jing-Yang Su, et al. Am J Cancer Res. 2024;14(2):407-428.
year: '2024'
doi: 10.62347/EJAA3388
journal_title: American Journal of Cancer Research
journal_nlm_ta: Am J Cancer Res
publisher_name: e-Century Publishing Corporation
keywords: Thyroid carcinoma | sodium iodide symporter | tyrosine kinase inhibitors
  | immune checkpoint inhibitors | redifferentiation
automl_pathway: 0.950712
figid_alias: PMC10915323__F1
figtype: Figure
redirect_from: /figures/PMC10915323__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10915323__ajcr0014-0407-f1.html
  '@type': Dataset
  description: The major signaling pathways of molecular targeted drugs. FL, FLT-3
    ligand; FLT-3, FMS-like tyrosine kinase-3; GDNF, glial cell-derived neurotrophic
    factor; GFRα, GDNF family receptor α; RET, rearranged during transfection; HGF,
    hepatocyte growth factor; MET, mesenchymal-epithelial transition factor; SCF,
    stem cell factor; c-KIT, proto-oncogene proteins c-kit; EGF, epidermal growth
    factor; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth
    factor; VEGFR, vascular endothelial growth factor receptor; PDGF, platelet-derived
    growth factor; PDGFR, platelet-derived growth factor receptor; FGF, fibroblast
    growth factor; FGFR, fibroblast growth factor receptor; PI3K (phosphatidylinositol-3
    kinase)/AKT/mammalian target of rapamycin (mTOR) signaling pathway; RAS/RAF/MEK/ERK
    signaling pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - HGF
  - IL6
  - SOS1
  - KITLG
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - GDNF
  - RAPGEF5
  - EGF
  - EGFR
  - RET
  - KIT
  - FLT3
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - KDR
  - FLT1
  - FLT4
  - PDGFRB
  - PDGFRA
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - SLC5A5
  - TPO
  - THPO
  - EGF
  - RAS
  - MEK
  - Nucleus
---
